InVivo Therapeutics to Present at the 113th FSX Broker Dealer Conference

CEO to Showcase Company’s Latest Advances in Spinal Cord Injury Treatment

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced CEO Frank Reynolds will showcase InVivo’s most recent breakthroughs and provide a business update to potential investors during the 113th FSX (Financial Services Exchange) Conference set for October 26-29 at the Ritz Carlton in Coconut Grove, Fla.

Reynolds will present at 10:40 a.m. on Friday, October 28 to deliver an overview of InVivo’s innovative biomaterial scaffold technology that provides structural support to a damaged spinal cord to promote healing, help prevent paralysis and improve recovery and prognosis for patients. The company is currently awaiting FDA approval to move forward with its first human clinical study for acute SCI treatment using its proprietary scaffold. The 10-patient pilot study is expected to begin in early 2012.

Established in 1983, FSX is one of the oldest, most trusted organizations in the industry for independent broker dealers. FSX quarterly conferences provide an opportunity for companies seeking exposure to interact with a network of broker dealer principals, investment bankers and others. For more information or to register for the event, visit www.fsx1.com.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, Mass. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.



CONTACT:

SS|PR
Lisa Kornblatt, 847-415-9330
[email protected]

KEYWORDS:   United States  North America  Florida  Massachusetts

INDUSTRY KEYWORDS:   Surgery  Health  Biotechnology  Clinical Trials  Research  FDA  Science

MEDIA:

Logo
 Logo

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.